… HER2-ultra-low metastatic breast cancer. The newly added … receptor-positive (HR+) metastatic breast cancer. Chemotherapy follows if … -ultra-low expression metastatic breast cancer. Furthermore, Enhertu … and HER2-low metastatic breast cancer patients who had …

… patients with HER2 positive metastatic breast cancer. News release. Daiichi Sankyo … pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). ClinicalTrials.gov … with HER2+ advanced/metastatic breast cancer: additional analyses of DESTINY …

This segment examines how clinicians should interpret progression free survival, safety, and response signals from DESTINY Breast09 within the context of established HER2 targeted evidence. Panelists discuss placing interim PFS findings alongside …

This segment addresses the complex and evolving decisions surrounding treatment sequencing after progression on initial HER2 targeted therapy. The discussion explores how clinicians integrate prior response duration, pattern of progression, and patient …

… clinical trial with vepdegestrant in metastatic breast cancer (7). Additionally, C4 Therapeutics and …

… wild-type, locally advanced or metastatic breast cancer. This indication applies to patients … gedatolisib in HR+/HER2- metastatic breast cancer and provides corporate update. News …

… coverage for “thrivers” living with metastatic breast cancer. Pirowski stressed the importance of …

… those with estrogen receptor–positive metastatic breast cancer. However, there are new challenges … landscape of sequencing ADCs in metastatic breast cancer. Ther Adv Med Oncol. Published …

… regimens for locally advanced or metastatic breast cancer.11–14 After systemic absorption …

… from 7,772 patients with metastatic breast cancer. Researchers evaluated 222 of these …